MECP2 and myeloid sarcoma: Therefore, studying the link between MeCP2 and BDNF and other downstream biological targets such as NGF [5,10], TNFα [6], and CX3CL1 [9] in MS may lead to new epigenetic therapeutic approaches to promote re-myelination and myelin repair in MS.